Zai Lab to Unveil First Global Data on Zocilurtatug Pelitecan for Small Cell Lung Cancer
Event summary
- Zai Lab will present first global data from a clinical trial evaluating zocilurtatug pelitecan (zoci) for extensive-stage small cell lung cancer (ES-SCLC) at ESMO Congress 2026.
- The Phase 1b/1c cohort explores the safety and efficacy of zoci in combination with atezolizumab with or without carboplatin.
- Results will be shared on October 26, 2026, during the SCLC session in Madrid.
- Zoci is a novel antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3), a validated therapeutic target in SCLC.
The big picture
Zai Lab’s presentation of zoci data at ESMO 2026 comes at a critical juncture for SCLC treatment, where aggressive and lethal solid tumors demand innovative therapies. The trial results could redefine first-line treatment options, particularly if zoci demonstrates superior safety and efficacy in combination regimens. This development aligns with broader industry trends toward targeted ADCs in oncology, potentially expanding Zai Lab’s footprint in the global biopharmaceutical market.
What we're watching
- Clinical Efficacy
- How the systemic and intracranial efficacy data of zoci will position it against existing treatments for ES-SCLC.
- Regulatory Pathway
- The pace at which Zai Lab can advance zoci through regulatory approvals following positive trial results.
- Market Differentiation
- Whether zoci’s potential best-in-class safety profile can sustain its competitive edge in the SCLC treatment landscape.
Related topics